Europeiska unionen - isländska - EMA (European Medicines Agency)

amgen europe b.v. - etelcalcetide hýdróklóríð - ofnæmisviðbrögð, seinni hluti - anti-parathyroid agents, calcium homeostasis - parsabiv er ætlað fyrir meðferð kalkvakaóhófi (shpt) í fullorðinn sjúklinga með langvarandi nýrnasjúkdóm (langvinnan) á blóðskiljun meðferð.

Europeiska unionen - isländska - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - orlistat - offita - Ónæmiskerfi, þó ekki mataræði - alli er ætlað fyrir þyngd tap í fullorðna sem eru of þung (líkami massi, Ætti, stærri 28 kg/m 2) og ætti að taka í tengslum með dálítið hitaeiningaskert, neðri-feitur mataræði.

Europeiska unionen - isländska - EMA (European Medicines Agency)

sanofi b.v. - sevelamer - renal dialysis; hyperphosphatemia - Öll önnur lækningavörur - renagel is indicated for the control of hyperphosphataemia in adult patients receiving  haemodialysis or peritoneal dialysis. renagel should be used within the context of a multiple therapeutic approach, which could include calcium supplements, 1,25 - dihydroxy vitamin d3 or one of its analogues to control the development of renal bone disease.

Europeiska unionen - isländska - EMA (European Medicines Agency)

ipsen pharma - cabozantinib (s)-malate - carcinoma, renal cell; carcinomas, hepatocellular - Æxlishemjandi lyf - renal cell carcinoma (rcc)cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc):in treatment-naïve adults with intermediate or poor risk,in adults following prior vascular endothelial growth factor (vegf)-targeted therapy. cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults. hepatocellular carcinoma (hcc)cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc) in adults who have previously been treated with sorafenib.

Europeiska unionen - isländska - EMA (European Medicines Agency)

pfizer europe ma eeig - tafamidis - amyloidosis - Önnur lyf í taugakerfinu - vyndaqel er ætlað fyrir meðferð transthyretin amyloidosis í fullorðinn sjúklinga með stigi-1 einkennum polyneuropathy að tefja útlæga taugasköddun skert.

Island - isländska - LYFJASTOFNUN (Icelandic Medicines Agency)

novo nordisk a/s* - norethisteronum acetat; estradiol - filmuhúðuð tafla

Island - isländska - LYFJASTOFNUN (Icelandic Medicines Agency)

novo nordisk a/s* - norethisteronum acetat; estradiolum inn - filmuhúðuð tafla - 1mg/0,5 mg

Island - isländska - LYFJASTOFNUN (Icelandic Medicines Agency)

novo nordisk a/s* - estradiol; norethisteronum acetat - filmuhúðuð tafla

Europeiska unionen - isländska - EMA (European Medicines Agency)

ipsen pharma - cabozantinib - skjaldkirtilsæxli - Æxlishemjandi lyf - meðferð hjá fullorðnum sjúklingum með framsækið, óleysanlegt, staðbundið langt gengið eða meinvörpað skjaldkirtilskrabbamein.

Europeiska unionen - isländska - EMA (European Medicines Agency)

roche registration gmbh  - pralsetinib - krabbamein, lungnakrabbamein - Æxlishemjandi lyf - gavreto is indicated as monotherapy for the treatment of adult patients with rearranged during transfection (ret) fusion-positive advanced non-small cell lung cancer (nsclc) not previously treated with a ret inhibitor.